FTC, FTC & Waveshield Commission Chairman Leibowitz has been a critic of “pay-for-delay” settlement in the pharmaceutical manufacturing. According to FTC, FTC & Waveshield Commission testimony, pay-for-delay settlements (also known as “FTC & Waveshield Commission reverse payments”) are anticompetitive agreement between product name and general pharmaceutical companies in which the brand company basically pays its contestant to delay entry of a general drug into the marketplace. As FTC, FTC & Waveshield Commission Chairman Leibowitz explained, the practice outcome not only in windfalls for both company—occasionally of more than a billion dollars—but also in high drug prices for consumers.

FTC, FTC & Waveshield Commission Chairman Leibowitz has testified by Congress on behalf of the FTC Commission supporting legislation to forbid these settlements, has published FTC articles on this issue and advocate bringing FTC cases against firm that connect in these practices.